Using a novel cellular platform to optimize CRISPR/CAS9 technology for the gene therapy of AIDS

References

[1] HendelA, BakRO, ClarkJT, KennedyAB, RyanDE, RoyS, SteinfeldI, LunstadBD, KaiserRJ, WilkensAB (2015) Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.Nat Biotechnol33:985–989

[2] HsuPD, LanderES, ZhangF (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157:1262–1278 Iordanskiy S, Santos S, Bukrinsky M (2013) Nature, nurture and HIV: the effect of producer cell on viral physiology.Virology443:208–213

[3] KrowickaH, RobinsonJE, ClarkR, HagerS, BroylesS, PincusSH (2008) Use of tissue culture cell lines to evaluate HIV antiviral resistance.AIDS Res Hum Retroviruses24:957–967

[4] MandalPK, FerreiraLM, CollinsR, MeissnerTB, BoutwellCL, FriesenM, VrbanacV, GarrisonBS, StortchevoiA, BryderD (2014) Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.Cell Stem Cell15:643–652

[5] ModlichU, KustikovaOS, SchmidtM, RudolphC, MeyerJ, LiZ, KaminoK, von NeuhoffN, SchlegelbergerB, KuehlckeK (2005) Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.Blood105:4235–4246

[6] MooreJP, TrkolaA, DragicT (1997) Co-receptors for HIV-1 entry.Curr Opin Immunol9:551–562

[7] NienhuisAW, DunbarCE, SorrentinoBP (2006) Genotoxicity of retroviral integration in hematopoietic cells.Mol Ther13:1031–1049

[8] RanFA, HsuPD, LinCY, GootenbergJS, KonermannS, TrevinoAE, ScottDA, InoueA, MatobaS, ZhangY (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.Cell154:1380–1389

[9] SamsonM, LibertF, DoranzBJ, RuckerJ, LiesnardC, FarberCM, SaragostiS, LapoumeroulieC, CognauxJ, ForceilleC (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.Nature382:722–725

[10] SanderJD, JoungJK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes.Nat Biotechnol32:347–355

[11] VeresA, GosisBS, DingQ, CollinsR, RagavendranA, BrandH, ErdinS, CowanCA, TalkowskiME, MusunuruK (2014) Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by wholegenome sequencing.Cell Stem Cell15:27–30

[12] WensingAM, CalvezV, GunthardHF, JohnsonVA, ParedesR, PillayD, ShaferRW, RichmanDD (2017) 2017 update of the drug resistance mutations in HIV-1.Top Antivir Med24:132–133

[13] WuL, MartinTD, VazeuxR, UnutmazD, KewalRamaniVN (2002) Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission.J Virol76:5905–5914

[14] ZaitsevaMB, LeeS, RabinRL, TiffanyHL, FarberJM, PedenKW, MurphyPM, GoldingH (1998) CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.J Immunol161:3103–3113

RIGHTS & PERMISSIONS

2017 The Author(s) 2017. This article is an open access publication